EMCDDA Home
  • EN
Search

Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV) in the framework of the Council Decision on new psychoactive substances

EMCDDA, Lisbon, May 2014

Publication type:

Risk assessments

Summary:

This report presents the data and findings of the risk assessment on the new psychoactive substance, 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this stimulant drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

Download as pdf (450Kb):

English (en)

Table of contents

  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on MDPV: a summary
  • Risk Assessment Report of a new psychoactive substance: MDPV
  • Annex 1: Technical report on MDPV
  • Council Implementing Decision of 25 September 2014 on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures
  • Participants of the risk assessment meeting

Pages:

30

Price:

free

ISBN/ISSN:

978-92-9168-749-7

Catalogue number:

TDAK14003ENN

Page last updated: Wednesday, 08 October 2014